A Phase 1, First In Human, Single-arm, Open-label Study Of Once A Day, Orally Administered Talazoparib (Bmn 673) In Patients With Advanced Or Recurrent Solid Tumors

Status: Completed

Phase of Trial: Phase I

Latest Information Update: 08 Nov 2021

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Talazoparib (Primary)
Indications Advanced breast cancer; Ewing's sarcoma; Ovarian cancer; Pancreatic cancer; Peritoneal cancer; Prostate cancer; Small cell lung cancer; Solid tumours
Focus Adverse reactions; First in man
Sponsors Medivation; Pfizer

14 Dec 2019 Results (n=494) of pooled analysis of five trials (EMBRACA, NCT01945775; ABRAZO, NCT02034916; NCT01286987, NCT03042910 & NCT02921919) assessing safety of talazoparib in patients with avanced breast cancer, presented at the 42nd Annual San Antonio Breast Cancer Symposium.
06 Sep 2019 Results of population pharmacokinetics of talazoparib in patients with advanced cancer published in the Journal of Clinical Pharmacology
15 Mar 2019 This trial has been completed in United Kingdom, according to European Clinical Trials Database.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com